Last reviewed · How we verify
Irbesartan/Amlodipine
Irbesartan/Amlodipine is a Angiotensin II receptor blocker / Calcium channel blocker combination Small molecule drug developed by Handok Inc.. It is currently in Phase 3 development for Hypertension.
This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance.
This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance. Used for Hypertension.
At a glance
| Generic name | Irbesartan/Amlodipine |
|---|---|
| Sponsor | Handok Inc. |
| Drug class | Angiotensin II receptor blocker / Calcium channel blocker combination |
| Target | AT1 receptor / L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Irbesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and the heart, reducing vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation. Together, these complementary mechanisms provide additive blood pressure reduction.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Peripheral edema
- Fatigue
- Headache
- Hyperkalemia
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients (PHASE4)
- Standardized Antihypertensive Treatment Protocol (NA)
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers (PHASE1)
- Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients (PHASE3)
- Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers (PHASE1)
- Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Irbesartan/Amlodipine CI brief — competitive landscape report
- Irbesartan/Amlodipine updates RSS · CI watch RSS
- Handok Inc. portfolio CI
Frequently asked questions about Irbesartan/Amlodipine
What is Irbesartan/Amlodipine?
How does Irbesartan/Amlodipine work?
What is Irbesartan/Amlodipine used for?
Who makes Irbesartan/Amlodipine?
What drug class is Irbesartan/Amlodipine in?
What development phase is Irbesartan/Amlodipine in?
What are the side effects of Irbesartan/Amlodipine?
What does Irbesartan/Amlodipine target?
Related
- Drug class: All Angiotensin II receptor blocker / Calcium channel blocker combination drugs
- Target: All drugs targeting AT1 receptor / L-type calcium channel
- Manufacturer: Handok Inc. — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension